{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:15:33Z","timestamp":1785161733672,"version":"3.55.0"},"reference-count":59,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1080\/14737140.2024.2445145","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T15:17:26Z","timestamp":1735312646000},"page":"1209-1219","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Practical insights into bispecific antibody therapy in multiple myeloma"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0401-9940","authenticated-orcid":false,"given":"Yumena","family":"Kawasaki","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of California Davis Medical Center, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Winger","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Division of Malignant Hematology, Cellular Therapy & Transplantation, University of California Davis Medical Center, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseem","family":"Esteghamat","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Division of Malignant Hematology, Cellular Therapy & Transplantation, University of California Davis Medical Center, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Division of Malignant Hematology, Cellular Therapy & Transplantation, University of California Davis Medical Center, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2774-0899","authenticated-orcid":false,"given":"Ryan","family":"Beechinor","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of California Davis Medical Center, Sacramento, CA, USA"},{"name":"San Francisco School of Pharmacy, University of California, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,1,12]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"e_1_3_4_4_1","unstructured":"SEER. Cancer stat facts: myeloma. National cancer institute. 2023 [cited 2024 Sep 9]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247015"},{"key":"e_1_3_4_6_1","unstructured":"National Comprehensive Cancer Network. Multiple myeloma (version 2. 2024 [cited 2024 Sep 8]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020179"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2140284"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231154809"},{"key":"e_1_3_4_11_1","unstructured":"Nooka AK. MD MPH. ASCO daily news. 2023 May 19 [cited 2024 Sep 9] Available from: https:\/\/dailynews.ascopubs.org\/do\/moving-through-crowded-space-do-emerging-immunotherapies-fit-multiple-myeloma-treatment"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01338-6"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"e_1_3_4_15_1","volume-title":"Tecvayli (teclistamab) [Package information]","year":"2024","unstructured":"Tecvayli (teclistamab) [Package information]. Horsham (PA): Janssen Biotech Inc; 2024 Nov."},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35107"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00741-2"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175539"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_4_21_1","volume-title":"Elrexfio (Elranatamab) [Package information]","year":"2024","unstructured":"Elrexfio (Elranatamab) [Package information]. New York (NY): Pfizer Inc; 2024 Nov."},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18909"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8036"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01689-6"},{"key":"e_1_3_4_26_1","volume-title":"Talvey (talquetamab) [package insert]","year":"2024","unstructured":"Talvey (talquetamab) [package insert]. Horsham (PA): Janssen Biotech, Inc; 2024 Nov."},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.05.003"},{"key":"e_1_3_4_28_1","volume-title":"Presented at: International Myeloma Society 6th Annual Nursing Symposium","author":"Mancia S","year":"2022","unstructured":"Mancia S, Farrell A, Louw K, et al. Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab for the treatment of relapsed\/refractory multiple myeloma. In: Presented at: International Myeloma Society 6th Annual Nursing Symposium; Los Angeles, CA; 2022 Aug 25\u201327. NS-001."},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-024-00740-z"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2401192"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186663"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.971"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284436"},{"key":"e_1_3_4_34_1","unstructured":"FDA. Ongoing | cancer accelerated approvals. FDA. 2024 Jan 29 [cited 2024 Sep 9] https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/ongoing-cancer-accelerated-approvals"},{"key":"e_1_3_4_35_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2024 [cited 2024 Dec 10]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05572515"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00808-8"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01107-6"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19633"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433516"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283003"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0049"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.01.025"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.016"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7524"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01114-7"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241268429"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.906"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187086"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00043-3"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022432"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2024.15.8.15"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02551-9"},{"key":"e_1_3_4_53_1","volume-title":"AACR Annual Meeting 2024","author":"Jagannath S","year":"2024","unstructured":"Jagannath S, Richter J, Dhodakar MV, et al. Linvoseltamab, a B-cell maturation antigen-targeted T-cell engaging bispecific antibody in patients with relapsed or refractory multiple myeloma, including difficult-to-treat subgroups. In: AACR Annual Meeting 2024; San Diego, CA; Abstract CT001. Presented. 2024 Apr 9."},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023616"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00750-2"},{"key":"e_1_3_4_56_1","unstructured":"Jaber N. FDA approves carvykti CAR T-Cell therapy for multiple myeloma. National Cancer Institute; 2022 Mar 30 [cited 2024 Apr 13] from https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2022\/fda-carvykti-multiple-myeloma"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000433"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00512"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.10.022"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8002"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8003"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2024.2445145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T09:08:37Z","timestamp":1737018517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2024.2445145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1080\/14737140.2024.2445145"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2024.2445145","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}